東北大学 大学院薬学研究科 薬理学分野

研究業績

学会発表リストは、こちら

佐々木の全論文リストは、こちら
See this page for Sasaki's all publications.

2021

原著論文 Original Papers

  1. Cheng A, Jia W, Kawahata I, Fukunaga K. A novel fatty acid-binding protein 5 and 7 inhibitor ameliorates oligodendrocyte injury in multiple sclerosis mouse mode. EBioMedicine (2021) 72: 103582.
  2. Ma W, Tan Y, Wang Y, Li Z, Li Z, Gu L, Mei R, Cheng A. Hydroxyl-Directed Ruthenium-Catalyzed peri-Selective C-H Acylmethylation and Annulation of Naphthols with Sulfoxonium Ylides. Org Lett (2021) 1c01684
  3. Cheng A, Kawahata I, Jia W, Fukunaga K. Impact of Fatty Acid-Binding Proteins in alpha-Synuclein-Induced Mitochondrial Injury in Synucleinopathy. Biomedicines (2021) 9(5):560.
  4. Cheng A, Wang Y, Shinoda Y, Kawahata I, Yamamoto T, Jia W, Yamamoto H, Mizobata T, Kawata Y, Fukunaga K. Fatty acid-binding protein 7 triggers α-synuclein oligomerization in glial cells and oligodendrocytes associated with oxidative stress. Acta Pharmacologica Sinica (2021) 0:1-11.
  5. Jia W, Kawahata I, Cheng A, Fukunaga K. The Role of CaMKII and ERK Signaling in Addiction. International Journal of Molecular Sciences (2021) 22(6):3189.
  6. Wang Y, Shinoda Y, Cheng A, Kawahata I, Fukunaga K. Epidermal Fatty Acid-Binding Protein 5 (FABP5) Involvement in Alpha-Synuclein-Induced Mitochondrial Injury under Oxidative Stress. Biomedicines (2021) 9(2):110. doi: 10.3390/biomedicines9020110.
  7. Yuan D, Cheng A, Kawahata I, Izumi H, Xu J, Fukunaga K. Single Administration of the T-Type Calcium Channel Enhancer SAK3 Reduces Oxidative Stress and Improves Cognition in Olfactory Bulbectomized Mice. Int J Mol Sci (2021) 22(2):741. doi: 10.3390/ijms22020741.
  8. Degawa T, Kawahata I, Izumi H, Shinoda Y, Fukunaga K. T-type Ca2+ channel enhancer SAK3 administration improves the BPSD-like behaviors in App NL-G-F/NL-G-F knock-in mice. J Pharmacol Sci (2021) 146(1):1-9. doi: 10.1016/j.jphs.2021.02.006.
  9. Jia W, Wilar G, Kawahata I, Cheng A, Fukunaga K. Impaired Acquisition of Nicotine-Induced Conditioned Place Preference in Fatty Acid-Binding Protein 3 Null Mice. Mol Neurobiol (2021) 58(5):2030-2045. doi: 10.1007/s12035-020-02228-2.
  10. Umaru BA, Kagawa Y, Shil SK, Arakawa N, Pan Y, Miyazaki H, Kobayashi S, Yang S, Cheng A, Wang Y, Shinoda Y, Kiniwa Y, Okuyama R, Fukunaga K, Yuji Owada. Ligand Bound Fatty Acid Binding Protein 7 (FABP7) Drives Melanoma Cell Proliferation Via Modulation of Wnt/β-Catenin Signaling. Pharm Res (2021) 38(3):479-490. doi: 10.1007/s11095-021-03009-9.
  11. Okonogi T, Sasaki T. Theta-range oscillations in stress-induced mental disorders as an oscillotherapeutic target. Frontiers in Behavioral Neuroscience, in press.
  12. Nishimura Y, Ikegaya Y, Sasaki T. Concurrent recordings of hippocampal neuronal spikes and prefrontal synaptic inputs from an awake rat. STAR Protocols, in press.
  13. Nishimura Y, Ikegaya Y, Sasaki T. Prefrontal synaptic activation during hippocampal memory reactivation. Cell Reports (2021) 34:108885. doi: 10.1016/j.celrep.2021.108885.
  14. Shikano Y, Ikegaya Y, Sasaki T. Minute-encoding neurons in hippocampal-striatal circuits. Current Biology (2021) 31: 1438-1449, 2021. doi:10.1016/j.cub.2021.01.032.
  15. Igata H, Ikegaya Y, Sasaki T. Prioritized experience replays on a hippocampal predictive map for learning. Proceedings of the National Academy of Sciences of the United States of America (2021) 118: e2011266118, 2021. doi:10.1073/pnas.2011266118.
  16. Iwasaki S, Sasaki T, Ikegaya Y. Hippocampal beta oscillations predict mouse object-location associative memory performance. Hippocampus (2021) 31: 503-511. doi:10.1073/pnas.2011266118.

総説 Review

  1. Okonogi T, Sasaki T. Optogenetic manipulation of the vagus nerve. Optogenetics (Springer Nature) (2021) 1293: 459-470. doi:10.1007/978-981-15-8763-4_30.

~2020

原著論文 Original Papers

  1. Cheng A, Kawahata I, Fukunaga K. Fatty Acid Binding Protein 5 Mediates Cell Death by Psychosine Exposure through Mitochondrial Macropores Formation in Oligodendrocytes. Biomedicines (2020) 8(12):635. doi:10.3390/biomedicines8120635.
  2. Shinoda Y, Wang Y, Yamamoto T, Miyachi H, Fukunaga K. Analysis of binding affinity and docking of novel fatty acid-binding protein (FABP) ligands. J Pharmacol Sci (2020) 143(4):264-271. doi:10.1016/j.jphs.2020.05.005.
  3. Shinoda Y, Haga Y, Akagawa K, Fukunaga K. Wildtype σ1 receptor and the receptor agonist improve ALS-associated mutation-induced insolubility and toxicity. J Biol Chem (2020) 295(51):17573-17587. doi:10.1074/jbc.RA120.015012.
  4. Izumi H, Kawahata I, Shinoda Y, Helmstetter FJ, Fukunaga K. SAK3 Administration Improves Spine Abnormalities and Cognitive Deficits in App NL-G-F/NL-G-F Knock-in Mice by Increasing Proteasome Activity through CaMKII/Rpt6 Signaling. Int J Mol Sci (2020) 21(11):3833. doi: 10.3390/ijms21113833.
  5. Haga H, Yamada R, Izumi H, Shinoda Y, Kawahata I, Miyachi H, Fukunaga K. Novel Fatty Acid-Binding Protein 3 Ligand Inhibits Dopaminergic Neuronal Death and Improves Motor and Cognitive Impairments in Parkinson's Disease Model Mice. Pharmacol Biochem Behav (2020) 191:172891. doi: 10.1016/j.pbb.2020.172891.
  6. Yabuki Y, Liu J, Kawahata I, Izumi H, Shinoda Y, Koga K, Ueno S, Shioda N, Fukunaga K. Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABA A Receptor. Int J Mol Sci (2020) 21(15):5525. doi: 10.3390/ijms21155525.
  7. Wilar G, Shinoda Y, Sasaoka T, Fukunaga K. Crucial Role of Dopamine D2 Receptor Signaling in Nicotine-Induced Conditioned Place Preference. Mol Neurobiol (2019) 56(12):7911-7928. doi: 10.1007/s12035-019-1635-x.
  8. Matsuo K, Cheng A, Yabuki Y, Takahata I, Miyachi H, Fukunaga K. Inhibition of MPTP-induced α-Synuclein Oligomerization by Fatty Acid-Binding Protein 3 Ligand in MPTP-treated Mice. Neuropharmacology (2019) 150:164-174. doi: 10.1016/j.neuropharm.2019.03.029.
  9. Cheng A, Shinoda Y, Yamamoto T, Miyachi H, Fukunaga K. Development of FABP3 ligands that inhibit arachidonic acid-induced α-synuclein oligomerization. Brain Res (2019) 1707:190-197. doi: 10.1016/j.brainres.2018.11.036.
  10. Cheng A, Shinoda Y, Matsuo K, Fukunaga K. FABP3 ligands inhibiting alpha-synuclein oligomerization in Neuro2A cells. Journal of Cerebral Blood Flow & Metabolism (2019) 39 (1_suppl); 422-422.
  11. Matsuo K, Cheng A, Yabuki Y, Takahata I, Miyachi H, and Fukunaga K. Inhibition of MPTP-induced α-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice. Neuropharmacology (2019) 150:164-74.
  12. Sun M, Shinoda Y, Fukunaga K. KY-226 Protects Blood-brain Barrier Function Through the Akt/FoxO1 Signaling Pathway in Brain Ischemia. Neuroscience (2019) 399:89-102. doi: 10.1016/j.neuroscience.2018.12.024.
  13. Nakazaki E, Yabuki Y, Izumi H, Shinoda Y, Watanabe F, Hishida Y, Kamimura A, Fukunaga K. Combined citicoline and docosahexaenoic acid treatment improves cognitive dysfunction following transient brain ischemia. J Pharmacol Sci (2019) 139(4):319-324. doi: 10.1016/j.jphs.2019.02.003.
  14. Wilar G, Anggadiredja K, Shinoda Y, Fukunaga K. Inhibition of Nicotine Dependence by Curcuminoid Is Associated with Reduced Acetylcholinesterase Activity in the Mouse Brain. Pharmacology (2018) 102(3-4):223-232. doi: 10.1159/000492154.
  15. Sun M, Izumi H, Shinoda Y, Fukunaga K. Neuroprotective effects of protein tyrosine phosphatase 1B inhibitor on cerebral ischemia/reperfusion in mice. Brain Res (2018) 1694:1-12. doi: 10.1016/j.brainres.2018.04.029.
  16. Izumi H, Shinoda Y, Saito T, Saido TC, Sato K, Yabuki Y, Matsumoto Y, Kanemitsu Y, Tomioka Y, Abolhassani N, Nakabeppu Y, Fukunaga K. The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice. Neuroscience (2018) 377:87-97. doi: 10.1016/j.neuroscience.2018.02.031.
  17. Husain N, Yabuki Y, Shinoda Y, Fukunaga K. Acute Treatment with T-Type Calcium Channel Enhancer SAK3 Reduces Cognitive Impairments Caused by Methimazole-Induced Hypothyroidism Via Activation of Cholinergic Signaling. Pharmacology (2018) 101(5-6):309-321. doi: 10.1159/000488083.
  18. Tamura S, Okada M, Kato S, Shinoda Y, Shioda N, Fukunaga K, Ui-Tei K, Ueda M. Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect. Sci Rep (2018) 8(1):2305. doi: 10.1038/s41598-018-20663-z.
  19. Yabuki Y, Matsuo K, Hirano K, Shinoda Y, Moriguchi S, Fukunaga K. Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice. Pharmacology (2017) 99(3-4):160-71. doi: 10.1159/000452839.
  20. Shinoda Y, Tagashira H, Bhuiyan MS, Hasegawa H, Kanai H, Zhang C, Han F, Fukunaga K. Corticosteroids Mediate Heart Failure-Induced Depression through Reduced σ1-Receptor Expression. PLoS One (2016) 11(10):e0163992. doi: 10.1371/journal.pone.0163992.
  21. Shinoda Y, Tagashira H, Bhuiyan MS, Hasegawa H, Kanai H, Fukunaga K. Haloperidol aggravates transverse aortic constriction-induced heart failure via mitochondrial dysfunction. J Pharmacol Sci (2016) 131(3):172-83. doi: 10.1016/j.jphs.2016.05.012.
  22. Tagashira H, Shinoda Y, Shioda N, Fukunaga K: Methyl pyruvate rescues mitochondrial damage caused by SIGMAR1 mutation related to amyotrophic lateral sclerosis. Biochim Biophys Acta (2014) 1840(12):3320-34. doi: 10.1016/j.bbagen.2014.08.012.
  23. Moriguchi S, Shinoda Y, Yamamoto Y, Sasaki Y, Miyajima K, Tagashira H, Fukunaga K: Stimulation of the Sigma-1 Receptor by DHEA Enhances Synaptic Efficacy and Neurogenesis in the hippocampal dentate gyrus of olfactory bulbectomized mice. PLoS One 8(4):e60863. (2013) doi: 10.1371/journal.pone.0060863.
  24. Shinoda Y, Fujita K, Saito S, Matsui H, Kanto Y, Nagaura Y, Fukunaga K, Tamura S, Kobayashi T: Acyl-CoA binding domain containing 3 (ACBD3) recruits the protein phosphatase PPM1L to ER-Golgi membrane contact sites. FEBS Lett. 586(19):3024-9. (2012) doi: 10.1016/j.febslet.2012.

総説 Review

  1. Fukunaga K, Izumi H, Yabuki Y, Shinoda Y, Shioda N, Han F. Alzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels. J Pharmacol Sci (2019) 139(2):51-58. doi: 10.1016/j.jphs.2018.11.014.
  2. 福永 浩司、篠田 康晴:Sigma-1受容体の生理機能と筋萎縮性側索硬化症との関連 Seikagaku (2017) 89(1):106-110. doi: 10.14952/seikagaku.2017.890106.
  3. Fukunaga K, Shinoda Y, Tagashira H: The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. J Pharmacol Sci (2015) 127(1):36-41. doi: 10.1016/j.jphs.2014.12.012.